Business Context and Reporting Period
Company: NewAmsterdam Pharma Company N.V.
Filing Type: Form 8-K (Current Report)
Date: July 30, 2025
Context: The Company announced full data from a prespecified Alzheimer's disease (AD) biomarker analysis within its Phase 3 BROADWAY clinical trial. The data was presented at the 2025 Alzheimer's Association International Conference (AAIC) and focuses on the effects of obicetrapib, a potent oral CETP inhibitor, on AD biomarkers in patients with cardiovascular disease.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial data and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The primary material event is the release of biomarker data from the BROADWAY trial, which was primarily designed to evaluate LDL-C lowering efficacy. The AD analysis covered 1,727 patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH).
- Primary Biomarker (p-tau217): Treatment with obicetrapib 10 mg daily for 12 months resulted in statistically significant lower absolute changes in plasma p-tau217 compared to placebo in the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215).
- Subgroup Analysis (ApoE4/E4 Carriers): In the subset of 29 patients with two E4 proteins, obicetrapib showed a mean percent change of -20.48% in p-tau217 versus placebo (p=0.010).
- Additional Biomarkers: Favorable trends were observed in neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), p-tau181, and the Aβ42/40 ratio.
- Safety: Safety in this population was not evaluated independently but was observed to be well-tolerated with results comparable to placebo in the overall BROADWAY study.
Guidance, Outlook, and Risks
Outlook: The Company intends to present these results to support the therapeutic potential of obicetrapib in reducing neurodegenerative risks. The data builds on Phase 2a proof of concept and preclinical data showing reductions in brain cholesterol metabolites.
Risks and Contingencies:
- Study Design Limitations: The AD analysis was based on a subset of patients from a trial designed for LDL-C reduction and was not controlled for baseline differences between treatment and placebo populations.
- Forward-Looking Uncertainty: Results from this analysis may not be indicative of results in later clinical trials or actual clinical outcomes. There is no guarantee that obicetrapib will receive regulatory approval for AD indications.
- Operational Risks: Risks include the ability to commercialize obicetrapib, negotiate favorable agreements, manage intellectual property claims, and source raw materials.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the p-tau217 reduction in the context of established Alzheimer's disease progression.
- Confirm the limitations of the study design, specifically the lack of baseline control for the AD subset analysis.
- Review the full presentation (Exhibit 99.2) and press release (Exhibit 99.1) for detailed data on the ApoE4/E4 subgroup.
- Assess the timeline and regulatory strategy for potential Alzheimer's disease indications versus the primary cardiovascular indication.
- Monitor upcoming clinical trial announcements to determine if these biomarker results translate into cognitive endpoint improvements.